Heart failure & cardiomyopathiesCohort study
Genotype Predicts Heart Failure Independent of Left Ventricular Ejection Fraction (LVEF), Peak VO2, and NT-proBNP Levels in Hypertrophic Cardiomyopathy
- Prospective cohort study
- observational
- single-centre
Authors' conclusion
Genetic status, peak VO2, log NT-proBNP, and LVEF independently predict HF outcomes in HCM.
Study context
- Population
- Genotyped patients with hypertrophic cardiomyopathy (median age 52 years, 33% women)
- Participants
- 505 patients
- Exposure
- Gene-positive vs gene-elusive hypertrophic cardiomyopathy (HCM)
- G+n = 219
- G-n = 286reference
- Outcome
- HF-related death or cardiac transplantation
- Follow-up
- Median 10.6 years
Main finding
As reported in the abstract
Hazard ratio
5.86
95% CI 2.26–15.25
P < 0.001
Events by group
G+ vs G-
HR 5.86 (95% CI 2.26–15.25); P < 0.001
- Log NT-proBNP independently associated with heart failure (HF) outcomes (HR 2.46; 95% CI 1.59-3.80)
- P < 0.001
- Peak VO2 independently associated with HF outcomes (HR 0.90; 95% CI 0.82-0.98)
- P < 0.001
- LVEF independently associated with HF outcomes (HR 0.74 per 5% increment; 95% CI 0.63-0.86)
- P < 0.001
- Primary outcome overall
- 34 patients (6.7%)
Observational data: associations, not effects.
Secondary outcomes
Cardiac death, arrhythmic events, all-cause mortality (overall)
- Cardiac death
- 60 patients (11.9%)
- Arrhythmic events
- 34 (6.7%)
- All-cause death
- 115 (22.8%)
Original publication
Genotype Predicts Heart Failure Independent of LVEF, Peak VO2, and NT-proBNP Levels in Hypertrophic Cardiomyopathy. JACC Heart Fail. Published 10 June 2026. doi:10.1016/j.jchf.2026.103149
Summarised from the published abstract; every number is checked against it